Clinical trials: Active Ulcerative Colitis, open to volunteers
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- RISE UP (NCT07136116)
- Where
- 29 sites in Japan
- Volunteers
- 200 people
- Sponsor
- AbbVie
Moderately to Severely Active Ulcerative Colitis (UC)
Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of IPG11406, an investigational oral drug, in adult patients with moderately to severely…
- Trial name
- NCT07535489
- Testing
- IPG11406
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Active Ulcerative Colitis
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121).
- Trial name
- NCT07665723
- Testing
- Afimkibart, Caffeine, Warfarin
- Where
- 18 sites in United States, Belgium and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a once-daily oral microbiome-targeted food supplement compared with matching placebo in adults with…
- Conditions
- Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Colitis
- Trial name
- AIM-IBD (NCT07619638)
- Testing
- Microbiome-Targeting Nutraceutical
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people
- Sponsor
- ENBIOSIS BIOTECHNOLOGIES
Inflammatory Bowel Diseases, Crohn Disease
Inflammatory Biomarkers and Disease Activity in Inflammatory Bowel Disease
This study aims to evaluate the diagnostic accuracy and clinical utility of routine blood-derived inflammatory biomarker ratios in assessing disease activity among adult patients with inflammatory bowel disease (IBD), including…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis (UC)
- Trial name
- NCT07788131
- Volunteers
- 120 people
- Sponsor
- Assiut University
Chronic Inflammatory Bowel Disease
Impact of a Structured Therapeutic Education Session on the Practice of Adapted Physical Activity in Chronic Inflammatory Bowel Diseases
Chronic inflammatory bowel diseases (IBD; including Crohn's disease and ulcerative colitis) significantly impact patients' quality of life.
- Trial name
- ETAP-MICI (NCT07305454)
- Testing
- Inflammatory Bowek Disk Questionnaires, Short-International Physical Activity Questionnaries
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Toulouse
Ulcerative Colitis (UC)
A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to preliminarily evaluate the efficacy and safety of SK08 in adult patients with active mild to moderate UC.
- Trial name
- NCT06725017
- Testing
- Live SK08 powder
- Volunteers
- 60 people
- Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.
Ulcerative Colitis (UC)
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
Micronutrient deficiencies are common in ulcerative colitis (UC). Selenium deficiency is associated with worse disease outcomes including disease flares and need for surgery.
- Trial name
- Selenium-UC (NCT07427017)
- Testing
- Selenium supplementation
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Northwestern University
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
- Trial name
- SHIFT-IBD (NCT07245394)
- Testing
- Guselkumab (Tremfya)
- Where
- 14 sites in Canada
- Volunteers
- 200 people
- Sponsor
- TIDHI Innovation Inc.
IBS, Ulcerative Colitis, Active
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
- Conditions
- IBS, Ulcerative Colitis, Active, Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), Healthy Controls
- Trial name
- NCT02421705
- Testing
- Sample collection
- Where
- Belgium
- Volunteers
- 99,999,999 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Ulcerative Colitis
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative Colitis on Advanced Therapies
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by superficial mucosal inflammation. Treatment aims to achieve and maintain remission, improve quality of life, and minimize complications.
- Trial name
- BOOST-UC (NCT06906445)
- Testing
- Fecal Microbial Transplantation, Anti-Inflammatory Diet, Advanced Therapy
- Where
- 6 sites in India
- Volunteers
- 220 people
- Sponsor
- All India Institute of Medical Sciences
Ulcerative Colitis
An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
Ulcerative colitis (UC) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. The hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus..
- Trial name
- NCT06838845
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- AbbVie
Ulcerative Colitis
Non-Invasive Biomarker Monitoring in UC on Biologics
Ulcerative colitis (UC) is a long-term inflammatory bowel condition. Many patients are treated with intravenous biologic drugs such as infliximab or vedolizumab.
- Trial name
- VIBRANT (NCT07920367)
- Where
- United Kingdom
- Volunteers
- 99 people
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Moderate to Severe Ulcerative Colitis
A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis
The study is being conducted to evaluate the safety, tolerability and pharmakokinetics of HRS-7085 in adults.
- Trial name
- NCT07760831
- Testing
- HRS-7085 tablets
- Where
- Moldova
- Volunteers
- 8 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies…
- Trial name
- NCT06979336
- Testing
- RO7837195
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 224 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis (UC)
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
The purpose of this protocol is to evaluate the safety and efficacy of Alpha-0261 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT07744646
- Testing
- Alpha-0261
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Ulcerative Colitis
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- SUNSCAPE-2 (NCT07185009)
- Testing
- Duvakitug
- Where
- 171 sites in United States, Argentina and 29 more
- Volunteers
- 751 people
- Sponsor
- Sanofi
Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)
Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults.
- Trial name
- APIMICI (NCT07191106)
- Testing
- adapted physical activity
- Where
- 2 sites in France
- Volunteers
- 72 people
- Sponsor
- Raincy Montfermeil Hospital Group
Colitis, Ulcerative
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years…
- Trial name
- ELEVATE-UCkids (NCT07470879)
- Testing
- Etrasimod
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Ulcerative Colitis (UC)
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
- Trial name
- NCT07686081
- Testing
- Ponesimod
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vanda Pharmaceuticals